微信公众号

官网二维码

中国癌症防治杂志

• 论文 • 上一篇    下一篇

AFP基因修饰树突状细胞瘤苗治疗肝移植瘤的实验研究

谢裕安;匡志鹏;李媛媛;罗小玲;吴继宁;   

  1. 广西肿瘤防治研究所实验研究部;
  • 收稿日期:2009-03-25 修回日期:2009-03-25 出版日期:2009-03-25 发布日期:2009-03-25

An experimental study for mAFP gene-modified DC tumor vaccine on transplanted liver cancer

XIE Yu-an,KUANG Zhi-peng,LI Yuan-yuan,et al.   

  1. (Department of Experimental Research,the Guangxi Cancer Institute,Nanning 530021,China
  • Received:2009-03-25 Revised:2009-03-25 Online:2009-03-25 Published:2009-03-25

摘要: 目的探讨pAdBM5-mAFP-DC瘤苗对C57BL/6J小鼠移植性肝癌发生、发展的阻断作用。方法40只C57BL/6J小鼠随机分为A、B、C、D、E组,每组8只。以免疫表达mAFP基因的重组腺病毒转染DC(pAdBM5-mAFP-DC)为A组;空pAdBM5质粒免疫为B组;以免疫表达mAFP基因的质粒DNA(pAdBM5-mAFP)为C组;单纯免疫DC为D组;以注射单纯PBS为对照组的E组。免疫方法:A组和D组在每只小鼠的右腋下注射5×10~5个细胞;B组和C组在每只小鼠的右腋下注射10.0μg质粒;E组仅注射0.1ml PBS。每周注射1次,连续免疫4次。在初次免疫后的第3周给所有小鼠移植Hepa1-6肝癌细胞。观察小鼠移植瘤的生长情况。于移植肿瘤第14天处死小鼠,观察成瘤情况,计算抑瘤率。结果A组有3只小鼠未长出移植瘤。处死小鼠称瘤重,发现A组瘤重与其他各对照组瘤重比较差异有显著性(P<0.05或0.01)。A、B、C、D各组肿瘤抑制率分别为:68.31%、13.23%、52.1%和38.54%,A组抑瘤率显著高于其它各组(P<0.05或0.01)。结论重组pAdBM5-mAFP-DC瘤苗免疫小鼠,可在一定程度上使小鼠获得免疫保护,降低肝癌的发生率。

关键词: 树突状细胞, 移植性肝癌, 树突状细胞瘤苗

Abstract: Objective To investigate the inhibitory effect of pAdBM5-mAFP-DC tumor vaccine on the transplanted liver cancer in mice.Methods 40 C57BL/6J mice were randomly divided into group A,B,C,D and E(8 mice in each group).Group A was immunized with mAFP gene-modified DC(pAdBM5-mAFP-DC);Group B was immunized with simple pAdBM5 plasmid; Group C was immunized with recombinant pAdBM5-mAFP plasmid;Group D was immunized with simple DC;Group E was injected with PBS.Each mouse in group A and D was immunized with 5×10~5 cells,in group B and C was immunized with 10.0μg plasmid DNA,in group E was injected with 0.1ml PBS.They were immunized once a week for a consecutive 4 weeks.At the third week,all the mice were transplanted with Hepa1-6 cells.All mice were killed 14 days after Hepa1-6 immunization.Results There was no tumorigenesis could be observed in 3 of 8 mice in group A.The average tumor weight of group A was far more lighter than that in the other groups,with the statistical significance(P<0.05 or 0.01).The tumor-inhibited rate of group A,B,C and D were 68.31%,13.23%,52.1%and 38.54%,respectively.The tumor-inhibited rate for group A was significantly higher than that in the other groups(P<0.05 or 0.01).Conclusion mAFP gene-modified DC tumor vaccine could induce immunoprotection and reduce the risk of tumorigenesis.

Key words: Dendritic cells, Transplanted liver cancer, DC tumor vaccine